The $13 Million Company Teaching the Immune System to Hunt Cancer
GT Biopharma, Inc. (NASDAQ: GTBP) is currently in the spotlight due to its clinical progress in immuno-oncology, a field that has attracted significant attention from investors. The company carries a market capitalization of approximately $13 million as of mid-May 2026, despite advancing three separate drug candidates into human trials. Its technology platform is exclusively licensed from the University of Minnesota, positioning it within a sector that giants in cancer therapy are investing heavily in.
GT Biopharma's innovative approach centers on employing the human immune system, specifically natural killer (NK) cells, to target and eliminate cancer cells. The company’s platform, known as TriKE® (Tri-specific Killer Engager), aims to activate NK cells to engage tumors more effectively. By utilizing three components within a TriKE molecule, the platform seeks to enhance the body’s existing defenses against cancer.
As of spring 2026, GT Biopharma has transitioned from being a one-drug entity to having three candidates in clinical development. The lead drug, GTB-3650, is currently in a Phase 1 trial targeting CD33-positive blood cancers. Meanwhile, GTB-5550 is in the early stages of development focusing on a protein called B7-H3, which is prevalent in numerous solid tumors, with a trial that recently dosed its first patient in May 2026.
The global oncology market is on track to expand significantly, with projections estimating growth from approximately $139 billion in 2025 to about $268 billion by 2034. With several established competitors, GT Biopharma’s current valuation raises questions regarding potential growth, especially as it attempts to attract investor interest in a high-risk environment characterized by the challenges faced by clinical-stage companies.
Despite its promising pipeline, GT Biopharma also faces challenges. It has no approved products or revenue, reportedly holding about $9 million in cash as of the end of Q1 2026, which is expected to sustain operations only through late 2026. As the company navigates these hurdles and continues to advance its candidates, investor scrutiny regarding its long-term prospects remains high.